Development of Gastro-Retentive Combination Formulation of Montelukast Sodium and Ketotifen Besilate for Allergic Rhinitis and Asthma
Keywords:
Combination Formulation, Floating, Gastro-Retentive, Similarity factorAbstract
Aim: The study aimed to develop a once-daily sustained-release gastroretentive combination formulation of ketotifen besilate and montelukast sodium using multilayer tablet technology and gastro-retentive systems for the treatment of allergic rhinitis and asthma.
Background: Ketotifen besilate and montelukast sodium are commonly used to manage allergic rhinitis and asthma. However, their conventional formulations often require multiple doses per day, leading to poor patient compliance. A gastro-retentive system allowing once-daily dosing could improve adherence and therapeutic outcomes.
Materials and Methods: A multilayer tablet was formulated with montelukast sodium in the immediate-release layer and ketotifen besilate in both the immediate- and sustained-release layers, using calcium silicate as a floating agent for gastric retention. Hydroxypropyl Methylcellulose (HPMC) controlled the sustained release of ketotifen, while the addition of super-disintegrants and a surfactant improved the release of poorly soluble montelukast. The lactose-microcrystalline cellulose ratio was adjusted to meet the target dissolution profile and comparative dissolution tests were conducted to assess similarity to the desired release profile.
Results: Comparative dissolution tests demonstrated high similarity between the combination formulation and the target release profile, with similarity factor (f2) values of 58.5 and 65.9. The formulation successfully allowed for different release rates of the two active ingredients, improving drug absorption and extending the duration of action.
Conclusion: The developed gastro-retentive formulation enabled a transition from twice-daily to once-daily dosing, enhancing patient compliance. The multilayer tablet design efficiently controlled the release profiles of both active ingredients, addressing limitations associated with the absorption sites of each drug.
Downloads
Metrics
References
Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol. 2001;108(1):S9-15. doi: 10.1067/mai.2001.115562, PMID 11449201.
Canonica GW, Blaiss MS. Antihistaminic, anti-inflammatory and antiallergic properties of second-generation antihistamines in allergic rhinitis. World Allergy Organ J. 2011;4(S3):S3-10. doi: 10.1097/WOX.0b013e31820bf78e.
Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. Ann Allergy Asthma Immunol. 2000;84(2):176-85; quiz 185. doi: 10.1016/ S1081-1206(10)62750-0, PMID 10719774.
Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419-25. doi: 10.1067/ma i.2002.121701, PMID 11897985.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160. doi: 1 0.1111/j.1398-9995.2007.01620.x, PMID 18331513.
Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy. 2005;35(6):723-7. doi: 10.1111/j.1365-2222.2005.02251.x, PMID 15969661.
Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004;113(3):415-9. doi: 10.1016/j.jaci.2003.11.034, PMID 15007339.
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-76. doi: 10.1016/j.jaci.2010.06.047, PMID 20816182.
Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20(1):213. doi: 10.3390/ijms20010213, PMID 30626077.
Williams JI, Gow JA, Klier SM, Mccue SL, Salapatek AM, Mcnamara TR. Non-clinical pharmacology, pharmacokinetics and safety findings for the antihistamine Ketotifen besilate. Curr Med Res Opin. 2010;26(10):2329-38. doi: 10.1185/0300799 5.2010.486753, PMID 20735291.
Yoon SK, Jin BH, kim CO, Park KS, Park MS, Chae DW. Pharmacokinetic modeling of Ketotifen for determination of optimal dosage regimen in pediatric patients with allergic rhinitis or urticaria. Pharmaceutics. 2024;16(3):334. doi: 10.3390/pharmaceu tics16030334, PMID 38543228.
Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepostatine besilate. Drug Metab Dispos. 2006;34(5):793-9. doi: 10.1124/dmd.105.0 07559, PMID 16455807.
Shep S, Dodiya S, Lahoti S, Mayee R. Swelling System: A novel approach towards gastroretentive drug delivery system. IGJPS. 2011;1(3):234-42. doi: 10.35652/IGJPS .2011.23.
Patel P, Philip G, Yang W, Call R, Horak F, LaForce C, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(6):551-7. doi: 10.1016/S1081-1206(10)61018-6, PMID 16400895.
Van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58(12):1268-76. doi: 10.1046/j.1398-9995.2003.002 61.x, PMID 14616102.
Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32(7):1020-8. doi: 10.1046/j.1365-2222.2002.01422.x, PMID 12100048.
Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338-44. doi: 10.1016/j.amjmed.2003.10.030, PMID 14984820.
Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(6):949-55. doi: 10.1067/mai.2002.124467, PMID 12063523.
Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128(4):1910-20. doi: 10.137 8/chest.128.4.1910, PMID 16236835.
Patel R, Naqvi SA, Griffiths C, Bloom CI. Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review. BMJ Open Respir Res. 2020;7(1):e000756. doi: 10.1136/bmjresp-2020-000756, PMID 33268342.
Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med. 2000; 162(4 pt 1):1297-301. doi: 10.1164/ajrccm.162.4.99120 46, PMID 11029334.
Polos PG. Montelukast is an effective monotherapy for mild asthma and for asthma with co-morbid allergic rhinitis. Prim Care Respir J. 2006;15(5):310-1; author reply 311. doi: 10.1016/j.pcrj.2006.07.003, PMID 16973416.
Knorr B, Holland S, Rogers JD, Nguyen HH, Reiss TF. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections. J Allergy Clin Immunol. 2000;106(3) Suppl:S171-8. doi: 10.1067/mai.2000.109424, PMID 10984399.
Altaş U, Altaş ZM, Öz F, Özkars MY. Alta¸s U, Alta¸s ZM, Öz F, Özkars MY. Evaluation of neuropsychiatric effects of montelukast–levocetirizine combination therapy in children with asthma and allergic rhinitis. Children (Basel). 2023;10(8):1301. doi: 10 .3390/children10081301, PMID 37628300
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
